William Blair & Company
CELGZ

William Blair & Company’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

William Blair & Company’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-75
Closed – – 1668
2018
Q1 		$0 Buy
+75
New +$49 ﹤0.01% 1642

Other funds holding CELGZ

CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BFA
Beaumont Financial Advisors Needham, Massachusetts $1.46B AUM 21.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

William Blair & Company's CELGZ Position: Q2 2018 in Review

William Blair & Company sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q2 2018, closing a stake of 75 shares.

William Blair & Company first reported a position in CELGZ in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 19 funds tracked by Wall St. Rank hold CELGZ as of Q2 2018.

  • William Blair & Company reported no remaining Celgene Corporation Contingent Value Rights position as of Q2 2018 after selling out during the quarter.
  • William Blair & Company sold 75 Celgene Corporation Contingent Value Rights shares in Q2 2018.
  • William Blair & Company first reported a position in Celgene Corporation Contingent Value Rights in Q1 2018 and held it in 1 quarter.
  • William Blair & Company's Celgene Corporation Contingent Value Rights position peaked at $0 in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q2 2018.

Based on William Blair & Company's 13F filing for Q2 2018, filed 13 Aug 2018.